SGLT2i and GLP-1 RA could be prescribed more widely to individuals with diabetes and obesity or high cardiovascular risk in all age groups to take advantage of the weight loss and cardiovascular protective effects. This evidence concerns the gene GLP1R and diabetes mellitus.